Centiva Capital, LP Atea Pharmaceuticals, Inc. Transaction History
Centiva Capital, LP
- $3.13 Billion
- Q1 2025
A detailed history of Centiva Capital, LP transactions in Atea Pharmaceuticals, Inc. stock. As of the latest transaction made, Centiva Capital, LP holds 3,500 shares of AVIR stock, worth $9,065. This represents 0.0% of its overall portfolio holdings.
Number of Shares
3,500Holding current value
$9,065% of portfolio
0.0%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding AVIR
# of Institutions
109Shares Held
48.3MCall Options Held
3.4KPut Options Held
14.5K-
Black Rock Inc. New York, NY9.12MShares$23.6 Million0.0% of portfolio
-
Bml Capital Management, LLC Zionsville, IN7.61MShares$19.7 Million18.41% of portfolio
-
Tang Capital Management LLC San Diego, CA4.8MShares$12.4 Million0.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.73MShares$12.2 Million0.0% of portfolio
-
Bain Capital Life Sciences Investors, LLC Boston, MA2.49MShares$6.44 Million2.49% of portfolio
About Atea Pharmaceuticals, Inc.
- Ticker AVIR
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,258,600
- Market Cap $216M
- Description
- Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an antiviral drug candidate that is in Phase II clinical trial for the treatment of patients with COVID-19. The ...